MELBOURNE, Australia, 18th May 2019: Today, DermaSensor, the medical device company that seeks to enable healthcare professionals to efficiently check for skin cancer, will present its game-changing technology concept to the Australasian College of Dermatologists (ACD) 52nd Annual Scientific Meeting (ASM) and the Australian Dermatology Nurses (ADNA) National Conference being held at the Melbourne Convention and Exhibition Centre.
The Annual Scientific Meeting of the Australasian College of Dermatologists is held for all College members and medical professionals with an interest in dermatology. The meeting is attended by registered dermatologists, trainees, other medical professionals and nurses, from Australia, New Zealand, South-East Asia and other countries.
DermaSensor’s Dr. Michael Bonning, Senior Director of Medical Affairs, Christian Orb, Commercial Director, ANZ and Martina Clark, Territory Business Manager VIC from the DermaSensor Team are in attendance conducting market research into the use-case for the DermaSensor device concept; a revolutionary, world-first technology, designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions.
“We are excited to present the potentially game-changing capabilities of DermaSensor’s technology concept to the most pre-eminent members of the Australasian dermatology community to rapidly and efficiently check for skin cancer,” explains Dr Bonning. “We look forward to introducing a skin health service that’s efficient, accurate and affordable,” he says.
This exciting breakthrough was achieved using Elastic Scattering Spectroscopy – a technology pioneered at Boston University and University College London that uses light to evaluate cellular and subcellular structures of the skin.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. This low-cost, easy-to-use device enables healthcare providers and patients to access fast, accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.
DermaSensor aims to improve the way general practitioners assess the skin. The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. This provides an immediate, objective result that’s typically more accurate than visual assessment alone.
Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and medical practitioners may spend less time on lengthy procedures.